On the stock market since 2014, it operates in the world of health and science. It has 297 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 42% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 39% a year on average.
Sales run at $63.2M a year. A small number, but proof the product has real buyers.
There is $48.7M in the vault; even if every debt were paid off, $20.2M would remain.
A loss of $2.3M against $63.2M in annual sales.
On our five-subject report card, KSIOF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: KSIOF is a high-risk stock — not yet profitable, and its future rides on its product catching on.